Neko Health, a body-scanning startup based in Stockholm, recently bagged $260 million in Series B funding. This recent capital injection skyrockets Neko’s valuation to $1.8B post-investment.
The funds raised will be utilized to propel Neko’s expansion into U.S markets, continue the development of its diagnostic tools, possibly through acquisitions, and establish more clinics to meet the burgeoning demand. A significant increase in the waitlist of over 100,000 individuals signals the high demand for Neko’s services.
Led by new investor, Lightspeed Venture Partners, the funding round also saw participation from General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico. The raise followed a Series A round in 2023 that had accumulated $65 million, provided by Spotify co-founder Daniel Ek’s investment firm, Prima Materia, among others.
Neko’s increasing success is in sync with changing demands in the healthcare industry, with an emphasis on preventative healthcare and technology utilization. Moreover, the startup aims to make its services more accessible by adding parameters to measure and offering various service tiers at different price points.
This funding will significantly aid Neko in intensifying its investment into product betterment, cementing it as a frontrunner in providing cost-effective, high-quality preventative diagnostics in the rapidly evolving healthcare industry.
Original source: Read the full article on TechCrunch
